Compare QFIN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QFIN | GH |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 14.1B |
| IPO Year | 2018 | 2018 |
| Metric | QFIN | GH |
|---|---|---|
| Price | $19.84 | $102.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 21 |
| Target Price | $36.85 | ★ $96.48 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 11-18-2025 | 10-29-2025 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | ★ 40.93 | N/A |
| EPS | ★ 6.93 | N/A |
| Revenue | ★ $2,752,357,572.00 | $902,569,000.00 |
| Revenue This Year | $16.96 | $35.00 |
| Revenue Next Year | N/A | $26.80 |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | 14.06 | ★ 30.38 |
| 52 Week Low | $17.61 | $29.91 |
| 52 Week High | $48.94 | $112.43 |
| Indicator | QFIN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 55.77 |
| Support Level | $18.71 | $96.28 |
| Resistance Level | $20.05 | $103.17 |
| Average True Range (ATR) | 0.67 | 3.88 |
| MACD | 0.26 | -0.94 |
| Stochastic Oscillator | 81.72 | 48.56 |
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.